Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Evaluation of genotoxic potential of peptides used in nuclear medicine (PSMA -617 and -11, and ubiquicidine 29-41) using a flow-cytometric, semi-automated analysis of micronuclei frequency in cell cultures

Texto completo
Autor(es):
de Carvalho, L. R. [1] ; Vieira, D. P. [1]
Número total de Autores: 2
Afiliação do(s) autor(es):
[1] Inst Pesquisas Energet & Nucl, Ctr Biotecnol, Lab Radiobiol, Av Lineu Prestes 2242, Sao Paulo, SP - Brazil
Número total de Afiliações: 1
Tipo de documento: Artigo Científico
Fonte: TOXICOLOGY REPORTS; v. 7, p. 304-316, 2020.
Citações Web of Science: 0
Resumo

Assays that rely on the assessment of frequency of micronuclei are important standard techniques currently used to quantify potential genotoxic damage after exposure to chemical or physical agents, such as ionizing radiation, or in pre-clinical studies, to assessment of the genotoxic potential of drugs or its components. The experiments are usually performed using conventional microscopy, but currently the protocols are being upgraded to automated approaches based on flow cytometry protocols based on the elimination of the plasma membrane by chemical agents, allowing quantification by flow cytometry. In this work, the genotoxic potential of peptides used as components of radiopharmaceuticals (PSMA-617 and 11 and Ubiquicidine) was evaluated exposing CHO-KI cells to a wide range of concentration (0.1X and 100X the maximum allowed concentration to human adults). Incubation with PSMA-11 or UBI29-41 did not induce genotoxicity. After 24 h of incubation, PSMA-617 induced genotoxicity only in non-practical concentration (100-fold). Results corroborate the safety of the pre-drugs and the wide detection range of technique. (AU)

Processo FAPESP: 17/50332-0 - Capacitação científica, tecnológica e em infraestrutura em radiofármacos, radiações e empreendedorismo a serviço da saúde (PDIp)
Beneficiário:Marcelo Linardi
Linha de fomento: Auxílio à Pesquisa - Programa Modernização de Institutos Estaduais de Pesquisa